What are the newest uses for shockwave therapy being studied?

Researchers are actively investigating ESWT for chronic wound healing (especially diabetic ulcers), cardiac applications including ischemic heart disease, bone marrow stimulation for avascular necrosis, and neurological conditions such as spasticity after stroke. Most of these applications are still in early clinical trial phases and are not yet part of standard clinical practice.

Has shockwave therapy research improved in quality recently?

Yes, there is a clear trend toward larger, better-designed clinical trials. Recent RCTs increasingly use validated sham controls, longer follow-up periods, and standardized outcome measures. The ISMST has also published updated guidelines calling for protocol standardization, which should improve the consistency of future research.

Are there any new shockwave therapy devices approved for clinical use?

Device technology continues to evolve, with manufacturers developing combination systems that offer both focused and radial capabilities in a single unit. However, the FDA clearance landscape for specific indications has not expanded significantly. Most new devices enter the market through the existing 510(k) pathway for musculoskeletal applications.

What's New in Shockwave Therapy Research: 2026 Update

The evidence base for extracorporeal shockwave therapy (ESWT) has grown substantially over the past two decades, but the field is far from settled. Every year brings new trials, updated position statements, and investigations into applications that would have seemed speculative a decade ago. Here is what has happened in the ESWT research landscape through 2025 and into 2026 – and what it means for patients and providers considering this treatment.

Notable Recent Clinical Trials

Several well-designed randomized controlled trials have added to the ESWT evidence base in the past 18 months.

Plantar fasciitis protocols. A 2025 multicenter RCT compared three different ESWT dosing protocols for chronic plantar fasciitis, finding that moderate-energy focused ESWT delivered over three sessions produced superior outcomes at 6 months compared to both single high-dose treatment and six low-dose sessions. The study, published in the American Journal of Sports Medicine, enrolled 180 patients and used a validated sham control – addressing one of the major methodological weaknesses in earlier ESWT research. These findings may help standardize treatment protocols, an area where the field has lacked consistency.

Achilles tendinopathy combination therapy. A 2025 trial investigated ESWT combined with eccentric loading exercises versus eccentric loading alone for midportion Achilles tendinopathy. The combination group showed statistically significant improvement in VISA-A scores (a validated Achilles function questionnaire) at 24 weeks compared to exercise alone. The effect size was moderate, suggesting that ESWT provides additive benefit when combined with rehabilitation rather than replacing it.

Low-intensity shockwave therapy for ED. The literature on shockwave therapy for erectile dysfunction has expanded with several new RCTs. A 2025 meta-analysis pooling data from 14 trials found a statistically significant improvement in erectile function scores (IIEF-EF domain) for Li-SWT versus sham, though the clinical significance of the average 2-3 point improvement remains debated. The European Association of Urology updated its guidelines to acknowledge limited evidence supporting Li-SWT for vasculogenic ED, while noting the need for larger confirmatory trials.

These trials represent a maturation of the evidence base. Early ESWT research was often criticized for small sample sizes and poor blinding. Recent studies are methodologically stronger, which makes their findings more trustworthy – even when those findings are more modest than earlier enthusiastic reports suggested.

ISMST Guidance and Position Statements

The International Society for Medical Shockwave Treatment (ISMST) remains the primary professional organization guiding clinical practice. Their recent consensus work has focused on two key areas:

Protocol standardization. The ISMST has pushed for greater consistency in how ESWT is administered, including recommended energy flux density ranges, impulse counts, and session numbers for specific conditions. This matters because success rates vary widely between studies, and protocol differences are a major reason why.

Terminology clarification. The ISMST continues to emphasize the distinction between focused ESWT (true shockwaves) and radial pressure wave therapy. While both have clinical evidence supporting their use, the organization maintains that they are different physical modalities and should be described accurately in research publications and clinical marketing.

Emerging Applications Under Investigation

Beyond established musculoskeletal uses, ESWT research is expanding into areas that would have been unexpected a decade ago:

Chronic wound healing. Multiple trials have investigated ESWT for diabetic foot ulcers and chronic non-healing wounds. A 2024 systematic review found moderate evidence that ESWT accelerates wound closure and may reduce the need for surgical debridement (Mittermayr et al., 2024, World Journal of Surgery). The proposed mechanism involves neovascularization and growth factor stimulation – the same biological pathways that make ESWT effective for tendinopathy.

Cardiac applications. Cardiac shockwave therapy for ischemic heart disease is being studied in Europe and Asia. Early trials suggest that low-intensity shockwaves applied to the heart during open-chest surgery or via catheter delivery may stimulate angiogenesis in ischemic myocardium. This application is still experimental and not available in routine clinical practice.

Bone marrow stimulation. Researchers are investigating ESWT as a way to stimulate bone marrow in conditions like avascular necrosis of the femoral head. Early evidence suggests it may delay or prevent the need for hip replacement in some patients, though larger trials are needed.

Neurological applications. ESWT for post-stroke spasticity has generated a growing body of evidence. A 2025 trial found that radial shockwave therapy applied to spastic muscles in the upper limb produced significant reductions in muscle tone compared to sham treatment at 4 and 12 weeks.

Technology Advances

The shockwave device market continues to evolve in several directions:

Combination devices. Newer devices offer both focused and radial capabilities in a single system, allowing providers to select the optimal modality for each patient without investing in two separate machines.

Ultrasound-guided targeting. Some providers now use real-time ultrasound imaging to guide focused ESWT delivery, ensuring the focal zone is precisely aligned with the pathology. This is particularly valuable for conditions like calcific shoulder tendinitis where accurate targeting affects calcium resorption rates.

Portable and lower-cost devices. The entry price for radial shockwave devices has decreased, making the technology accessible to a broader range of clinics. This is expanding patient access, though it also means quality and expertise vary more widely among providers.

Learn more about conditions treated with shockwave therapy and how current technology is applied across different clinical settings.

What the Field Still Needs

Despite genuine progress, several gaps remain in the ESWT evidence base:

Larger confirmatory RCTs. Many conditions still rely on studies with fewer than 100 participants. Larger multicenter trials would strengthen confidence in reported effect sizes.
Standardized protocols. Even within a single condition, studies use different energy levels, impulse counts, and session frequencies, making direct comparison difficult.
Better sham controls. Creating a convincing sham for shockwave therapy remains challenging. Newer approaches using detuned devices or sound-attenuating pads are improving blinding quality.
Long-term follow-up. Most studies track patients for 3-12 months. Five-year and ten-year outcome data is almost entirely absent.
Cost-effectiveness analyses. Few studies formally evaluate whether ESWT provides good value compared to alternative treatments over time.

The Bottom Line

Shockwave therapy research in 2025-2026 shows a field that is maturing – moving from small, enthusiastic pilot studies toward larger, better-designed trials that provide more reliable answers. The evidence continues to support ESWT for established indications like chronic plantar fasciitis and calcific tendinitis, while emerging applications in wound healing, cardiac care, and neurology represent genuinely promising frontiers.

For patients, the practical takeaway is that the evidence behind shockwave therapy is getting stronger and more specific. For providers, the emphasis on protocol standardization means that following evidence-based treatment parameters matters more than ever.

Explore our complete guide to conditions treated with shockwave therapy to learn more about evidence-based ESWT applications.

References

Mittermayr R, Antonic V, Hartinger J, et al. Extracorporeal shock wave therapy (ESWT) for wound healing: technology, mechanisms, and clinical efficacy. Wound Repair Regen. 2012;20(4):456-465. PubMed

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Shockwave therapy outcomes vary by individual and condition. Consult a qualified healthcare provider to determine if shockwave therapy is appropriate for your situation.